Close Menu

heart disease

The partnership will provide new point-of-care lipid testing devices to remote sites in Latin America, the Caribbean, and Asia-Pacific.

The firm said that it has begun developing its own products using synthetic affinity reagent technology acquired five years ago from the University of Leicester.

Prevencio said that the agreement with Microsoft involves sales of cardiac blood tests to hospitals, life science companies, and contract research organizations.

The Ottawa-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.

The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.

The researchers said the test performed well in distinguishing patients with or without complications and proved itself better than frequently used clinical variables.

Agilent has partnered with the National University of Singapore and National University Hospital to establish the S$38 million ($27.4 million) research and development facility in Singapore.

The merger is aimed at expanding Salveo’s diagnostics capabilities and improving communication with providers and patients.

Ortho's assay, which aids in quickly and accurately diagnosing heart attacks, runs on its new Vitros XT 7600 Integrated System, among other Ortho systems.

The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.

Pages